Clinical Trial Update: Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) [Phase 3]

View source ↗

Summary

Phase III trial evaluating a recombinant Respiratory Syncytial Virus vaccine produced in CHO cells is currently recruiting. No results are reported yet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Recombinant Respiratory Syncytial Virus Vaccine)

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Respiratory Syncytial Virus (RSV) | Phase 3 | Status: RECRUITING